Chen SG, Stribinskis V, Rane MJ, Demuth DR, Gozal E, Roberts AM, et al
It activates two of the same three receptors (GLP-1 and GIP), missing only the glucagon pathway
The conversation about GLP-1 drugs has been focused on hunger
Similarly, Novo Nordisk makes both insulin degludec (Tresiba) and semaglutide (Ozempic), plus a combination product called Xultophy that pairs insulin degludec with liraglutide
At Preferred Dermatology, we understand that there is no single GLP1 option that is universally best for weight loss
The process requires the same tools that prevent muscle loss in the first place: consistent resistance training and adequate protein intake